tiprankstipranks
Trending News
More News >
Link-Asia International Medtech Group Ltd. (HK:1143)
:1143
Hong Kong Market
Advertisement

Link-Asia International Medtech Group Ltd. (1143) AI Stock Analysis

Compare
0 Followers

Top Page

HK:1143

Link-Asia International Medtech Group Ltd.

(1143)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
HK$0.50
▲(19.05% Upside)
The overall stock score of 47 reflects the company's mixed financial performance, with stable equity but declining revenues and inconsistent cash flow. Technical indicators suggest neutral to weak momentum, and valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors combined indicate potential risks and challenges for investors.

Link-Asia International Medtech Group Ltd. (1143) vs. iShares MSCI Hong Kong ETF (EWH)

Link-Asia International Medtech Group Ltd. Business Overview & Revenue Model

Company DescriptionLink-Asia International MedTech Group Limited, an investment holding company, provides electronic manufacturing services (EMS) for the telecommunications, security, car electronics, home appliances, other consumer, and industrial electronic products. The company operates through four segments: EMS, Distribution of Communications Products, Securities and Other Assets Investment, and Real Estate Supply Chain Services. It is also involved in the trade of personal care products, business telephone systems, and telecommunication products; manufacture and sale of telecommunications and other products, and consumable electronic products; sale of audio equipment; and provision of consultancy services, as well as pre-pregnancy care and assisted reproductive services. In addition, the company offers equity investment and property agency services; and real estate advisory and purchase services. It operates in the People's Republic of China, the United States, Switzerland, France, Poland, the United Kingdom, Belgium, Russia, Thailand, Malaysia, Brazil, and internationally. The company was formerly known as Link-Asia International Co. Ltd. and changed its name to Link-Asia International MedTech Group Limited in December 2020. Link-Asia International MedTech Group Limited was founded in 1992 and is headquartered in Tsim Sha Tsui, Hong Kong.
How the Company Makes MoneyLink-Asia International Medtech Group Ltd. generates revenue primarily through the sale of its medical devices and health-related products. The company may partner with healthcare providers, hospitals, and clinics to distribute its products, ensuring wide market access. Additionally, revenue might be augmented through research and development collaborations with other medtech companies, as well as potential government contracts or grants for developing new medical technologies. The company's success in generating revenue is also contingent upon regulatory approvals, market demand for its products, and its ability to innovate and address emerging healthcare needs.

Link-Asia International Medtech Group Ltd. Financial Statement Overview

Summary
Link-Asia International Medtech Group Ltd. shows a mixed financial profile. While there is stability in equity and a balanced capital structure, the company faces challenges with declining revenues, inconsistent cash flow, and volatile net profit margins. The positive EBIT margin in 2024 is a positive sign, but overall financial health needs improvement.
Income Statement
45
Neutral
Link-Asia International Medtech Group Ltd. has shown mixed results over recent years. The company experienced declining revenues with a negative growth trend from 2019 to 2024, particularly from 2021 to 2024. While gross profit margins remained relatively stable, net profit margins were volatile, indicating potential profitability issues. The positive EBIT margin in 2024 is a welcome improvement, although historical EBIT margins were negative.
Balance Sheet
55
Neutral
The company's balance sheet reveals a stable equity position with a moderate debt-to-equity ratio, indicating a balanced capital structure. The equity ratio has improved over time, suggesting a strengthening financial foundation. However, the fluctuating total debt and liabilities pose potential risks to financial stability.
Cash Flow
40
Negative
Cash flow analysis indicates inconsistent cash flow management. Operating cash flow was negative in several years, impacting free cash flow generation. Though there was a significant improvement in free cash flow in 2022, the lack of consistent positive cash flow raises concerns about long-term liquidity.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue479.32M502.00M529.25M675.52M595.02M
Gross Profit123.60M136.87M101.40M144.89M154.71M
EBITDA4.78M40.49M-14.06M-4.54M-116.52M
Net Income8.04M5.26M-54.04M-46.40M-173.05M
Balance Sheet
Total Assets880.14M776.42M659.23M677.98M657.40M
Cash, Cash Equivalents and Short-Term Investments312.05M271.57M252.21M146.80M167.66M
Total Debt86.60M26.75M51.08M61.20M70.19M
Total Liabilities343.25M287.69M297.22M311.98M361.47M
Stockholders Equity536.53M486.66M359.86M365.88M295.46M
Cash Flow
Free Cash Flow-75.67M-132.09M99.60M-122.55M-45.85M
Operating Cash Flow-73.19M-129.29M107.55M-100.45M-15.04M
Investing Cash Flow49.83M39.98M-547.00K3.31M-96.19M
Financing Cash Flow66.31M101.84M2.20M74.19M35.17M

Link-Asia International Medtech Group Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.42
Price Trends
50DMA
0.42
Negative
100DMA
0.38
Positive
200DMA
0.35
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
50.11
Neutral
STOCH
48.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1143, the sentiment is Positive. The current price of 0.42 is above the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.42, and above the 200-day MA of 0.35, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.11 is Neutral, neither overbought nor oversold. The STOCH value of 48.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1143.

Link-Asia International Medtech Group Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
47
Neutral
HK$94.20M13.80-0.84%-25.16%-160.31%
45
Neutral
132.89M-1.85100.35%-33.09%-107.58%
43
Neutral
79.44M18.5591.40%21.86%0.00%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1143
Link-Asia International Medtech Group Ltd.
0.42
-1.56
-78.79%
HK:0328
Alco Holdings
1.16
-4.11
-77.99%
DE:FTQ0
China Fortune Holdings Limited
0.01
-0.01
-50.00%
DE:UPZ
Superactive Group Company Limited
HK:8147
Millennium Pacific Group Holdings Ltd
0.47
0.16
51.61%

Link-Asia International Medtech Group Ltd. Corporate Events

China Energy Storage Technology Reports Interim Loss Amid Revenue Decline
Aug 29, 2025

China Energy Storage Technology Development Limited reported its unaudited consolidated interim results for the first half of 2025, revealing a significant decline in revenue and profit compared to the same period in 2024. The company experienced a net loss of HK$16.5 million, attributed to decreased revenue and increased finance costs, which may impact its market position and stakeholder confidence.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.

China Energy Storage Technology Ends Joint Placing Agreement
Aug 19, 2025

China Energy Storage Technology Development Limited announced the lapse of its Joint Placing Agreement due to unmet conditions by the deadline, resulting in the cessation of the planned Placing. The company assured stakeholders that this development will not adversely affect its operational or financial standing.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.

China Energy Storage Technology Development Ltd. Announces Board Meeting for Interim Results
Aug 15, 2025

China Energy Storage Technology Development Limited has announced a board meeting scheduled for August 29, 2025. The meeting will focus on approving the interim results for the first half of 2025, considering the payment of an interim dividend, and addressing other business matters. This announcement signifies the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.

China Energy Storage Extends Long Stop Date for Share Placement
Jul 29, 2025

China Energy Storage Technology Development Limited has announced a further extension of the Long Stop Date for the placement of new shares under a general mandate. The extension, now set to 19 August 2025, allows additional time for fulfilling conditions precedent in the Joint Placing Agreement. This move is seen as commercially reasonable and in the interest of the company and its shareholders, although the completion of the placing remains uncertain.

Leadership Change at China Energy Storage Technology Development Limited
Jul 24, 2025

China Energy Storage Technology Development Limited has announced a change in its executive leadership. Ms. Lin Xiaoshan has resigned from her position as executive director to focus on other business commitments, and Ms. Wu Jingjing has been appointed as her successor. Ms. Wu brings over a decade of experience in corporate publicity planning and marketing management, which is expected to enhance the company’s strategic communications and market presence. Her appointment is anticipated to support the company’s growth and strengthen its industry positioning.

China Energy Storage Technology Development Updates Board Structure
Jul 24, 2025

China Energy Storage Technology Development Limited, formerly known as Link-Asia International MedTech Group Ltd., has announced its updated list of directors and their roles within the company. The board comprises executive directors, including Mr. Lin Dailian as Chairman, and independent non-executive directors. The announcement details the composition of three key board committees, highlighting the leadership and membership roles of the directors. This restructuring could potentially impact the company’s governance and strategic direction, influencing its positioning in the energy storage sector.

China Energy Storage Technology Expands with New Cambodian Subsidiary
Jul 23, 2025

China Energy Storage Technology Development Limited has announced the establishment of a new wholly-owned subsidiary, Telefield (Cambodia) Electronic Company Limited (TCE), in Cambodia. This strategic move aims to capitalize on tax benefits for importing materials from China and exporting products to the US, with an investment of approximately USD 5 million planned over the next 12 months. The company expects mass production to commence by the end of 2025, potentially expanding its customer base in the US market.

China Energy Storage Extends Share Placing Deadline
Jul 15, 2025

China Energy Storage Technology Development Limited has announced an extension of the Long Stop Date for the placing of new shares under a general mandate. The extension, agreed upon with the Joint Placing Agent, moves the deadline from July 15, 2025, to July 29, 2025, allowing more time to fulfill conditions precedent in the Joint Placing Agreement. The directors believe the extension is commercially reasonable and in the best interests of the company and its shareholders. The placing may still be subject to conditions, and stakeholders are advised to exercise caution.

Link-Asia International Medtech Group Ltd. Announces New Share Placing
Jun 23, 2025

Link-Asia International Medtech Group Ltd. has announced a placing agreement to issue up to 44,856,000 new shares, representing about 20% of its current share capital, at a price of HK$0.33 per share. This move is expected to raise approximately HK$14.5 million in net proceeds, which the company plans to use for acquiring energy storage products. The shares will be placed with at least six independent third-party investors, and the transaction is subject to certain conditions being met, indicating potential implications for the company’s financial strategy and market positioning.

China Energy Storage Technology Development Limited Rescinds Board Lot Size Change
Jun 20, 2025

China Energy Storage Technology Development Limited announced the lapse of its proposed change in board lot size, which was initially intended to increase from 4,000 shares to 8,000 shares. This decision follows the lapse of the Rights Issue, indicating a strategic shift that may impact the company’s market operations and investor relations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 20, 2025